 Home > Medical News > Medical Research Articles > Bayer and Excientia will explore artificial intelligence in drug discovery

Bayer and Excientia will explore artificial intelligence in drug discovery

 Last Update: 2021-02-19
 Source: Internet
 Author: User

Tags

new drugs market

executive board member

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

collaboration between Bayer and UK-based Exscientia will accelerate the discovery of small molecule drugs, with a focus on cardiovascular disease and oncology.The companies announced that they will use artificial intelligence (AI) to further develop candidates for Bayer's three projects in the field of cardiovascular disease (CVD) and oncology.Under the terms of the deal, Excientia will begin three projects, both of which have agreed on targets and are eligible for funding of up to 203 million pounds, including "advance and research payments, short-term and clinical milestones.""We are driving the digital transformation of research and development because we believe that digital technologies such as artificial intelligence can simplify and accelerate the discovery and development of new drugs for patients," said Dr. Joerg Moeller, executive committee member of Bayer AG's pharmaceutical division.He continued: "The partnership with Excientia is expected to help us reach project milestones earlier, while accelerating the timeline by more accurately identifying the right drug targets and potential customer structures." As partpartnership, Excientia will use its Center Chemist AI drug discovery platform, including its "evolutionary computing" and deep learning algorithms, to identify and optimize new drug candidates. （cyy123.com）

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Supply 6-Diazo-5-oxo-L-norleucine 157-03-9

CAS No.: 157-03-9

Pharmacy Grade

$1900.00/G FOB

LASALOCID A SODIUM SALT CAS NO 25999-20-6

CAS No.: 25999-20-6

Industrial Grade, Feed Grade, Food Grade, Pharma Grade

$11.11/KG EXW

Tirzepatide CAS 2023788-19-2 99% Hot Sale Pharmaceutical Best Service Pharmaceutical Producer

CAS No.: 2023788-19-2

pharm grade

$140.00/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.